175 related articles for article (PubMed ID: 34039982)
1. How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.
Wang X; Wang L; Bu H; Zhang N; Yue M; Jia Z; Cai L; He J; Wang Y; Xu X; Li S; Xiao K; Yan K; Tian K; Han X; Huang J; Yao J; Liu Y
NPJ Breast Cancer; 2021 May; 7(1):61. PubMed ID: 34039982
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
Li J; Dong P; Wang X; Zhang J; Zhao M; Shen H; Cai L; He J; Han M; Miao J; Liu H; Yang W; Han X; Liu Y
Histopathology; 2024 May; ():. PubMed ID: 38747491
[TBL] [Abstract][Full Text] [Related]
3. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
[TBL] [Abstract][Full Text] [Related]
5. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
6. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.
Yue M; Zhang J; Wang X; Yan K; Cai L; Tian K; Niu S; Han X; Yu Y; Huang J; Han D; Yao J; Liu Y
Virchows Arch; 2021 Sep; 479(3):443-449. PubMed ID: 34279719
[TBL] [Abstract][Full Text] [Related]
7. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
[TBL] [Abstract][Full Text] [Related]
8. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
Mod Pathol; 2024 Apr; 37(6):100485. PubMed ID: 38588885
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
10. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
11. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
[TBL] [Abstract][Full Text] [Related]
12. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
[TBL] [Abstract][Full Text] [Related]
13. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study.
Chen C; Ma X; Li Y; Ma J; Yang W; Shui R
Pathol Res Pract; 2022 Oct; 238():154137. PubMed ID: 36152566
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
16. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Grabenstetter A; Jungbluth AA; Frosina D; Hoda R; Dos Anjos CH; Patil S; Sevilimedu V; Weigelt B; Reis-Filho JS; Zhang H; Traina T; Robson ME; Brogi E; Wen HY
Am J Surg Pathol; 2021 Sep; 45(9):1274-1281. PubMed ID: 34115674
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
19. A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Taylor CR; Jadhav AP; Gholap A; Kamble G; Huang J; Gown A; Doshi I; Rimm DL
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):263-269. PubMed ID: 30640753
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]